Talimogene Laherparepvec (T-VEC) for carcinoma, squamous cell

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 8 Mar 2018: Trial registered, NCT03458117
  2. 19 Apr 2018: Trial started, NCT03458117

The trials

NCT03458117: T-VEC in Non-melanoma Skin Cancer

State
Completed
Phase
Phase 1
People
26 taking part
Started
19 Apr 2018
Primary completion
4 Feb 2022
Arms
Talimogene Laherparepvec (T-VEC)
Results
None posted
  1. 8 Mar 2018: Trial registered
  2. 19 Apr 2018: Trial started
  3. 15 Mar 2022: Trial completed

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

About the treatment

Kind of treatment: Gene therapy.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.